Advertisement

Topics

Oncolytics Company Profile

15:41 EDT 21st September 2017 | BioPortfolio

The Company's technologies are based on discoveries arising from research conducted at the University of Calgary. Dr. Coffey, VP Product Development for the Company was instrumental in these discoveries, and continues to be instrumental in the product development process.

The Company was formed in 1998, to explore the natural oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway.



The product being developed by the Company may represent a novel treatment for certain tumor types and some cellular proliferative disorders. The Company’s product is a virus that is able to replicate specifically in, and hence kill, certain tumor cells both in tissue culture as well as in a number of animal models.



The Company’s product for human use, REOLYSIN®, is the reovirus. This virus has been demonstrated to replicate specifically in tumor cells bearing an activated Ras pathway. Activating mutations of Ras and upstream elements of Ras may play a role in greater than two thirds of all potential tumors.

Location

210, 1167 Kensington Crescent
NW Calgary
AB T2N 1X7

Contact

Phone: (403) 670-7377
Fax: (403) 283-0858
Email: dougballonc@aol.com


News Articles [41 Associated News Articles listed on BioPortfolio]

Oncolytics Biotech Inc. (ONCYF) Downgraded by ValuEngine to Sell

Oncolytics Biotech traded up 0.75% during trading on Friday, hitting $0.41. The company's stock had a trading volume of 33,326 shares.

Oncolytics Biotech’s Reolysin Granted Fast Track Designation by the FDA in Metastatic Breast Cancer

CALGARY, May 8, 2017 /PRNewswire/ – Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) announced today that the United States Food and Drug Administration (FDA) has gr...

Oncolytics Biotech nets $Cdn9.4mm through public offering

Oncolytics Biotech Inc. (immuno-oncology) netted $Cdn9.4mm ($7mm) through the public sale of 14.3mm units at $Cdn0.70 apiece. Each unit consisted of one common share and a five-year warrant for a comm...

Oncolytics Biotech nets $Cdn10.8mm through public offering

Oncolytics Biotech Inc. (immuno-oncology) netted $Cdn10.8mm ($8mm) through the public sale of 16.4mm units at $Cdn0.70 apiece. Each unit consisted of one common share and a five-year warrant for a com...

Oncolytics Biotech (ONCY) Given News Sentiment Score of 0.70

News headlines about Oncolytics Biotech have trended very positive this week, AlphaOne Sentiment Analysis reports. AlphaOne, a subsidiary of Accern, ranks the sentiment of media coverage by analyzing ...

Windtree Therapeutics (WINT) versus Oncolytics Biotech (NASDAQ:ONCY) Critical Analysis

Windtree Therapeutics and Oncolytics Biotech are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, an...

Oncolytics’ Reolysin gets fast track designation from FDA

Oncolytics Biotech’s proprietary immuno-oncology viral agent for metastatic breast cancer has received a fast track designation from the United States Food and Drug Administration (FDA). The company...

Oncolytics raises C$10M in follow-on

Drugs and Medications [0 Results]

None

PubMed Articles [3 Associated PubMed Articles listed on BioPortfolio]

The relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics: a pilot study with Michigan oncology practices.

The Michigan Oncology Quality Consortium (MOQC) is a continuous quality improvement collaborative seeking to improve oncology care in Michigan, including for patients taking oral chemotherapy. The aim...

Implementing a Method for Evaluating Patient-Reported Outcomes Associated With Oral Oncolytic Therapy.

The paradigm shift in health care toward value-based reimbursement has brought emphasis to providing better quality of care to patients with chronic diseases, including patients with cancer. In accord...

Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.

Oncolytic viruses (OVs) are emerging as powerful anti-cancer agents and are currently being tested for their safety and efficacy in patients. Reovirus (Reolysin), a naturally occurring non-pathogenic,...

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Oncolytics Biotech Inc.

Oncolytics Biotech Inc. was formed in 1998 to develop its proprietary product, REOLYSIN®, as a potential therapeutic for a wide variety of human cancers. Oncolytics has completed five clinical trials...

Oncolytics

The Company's technologies are based on discoveries arising from research conducted at the University of Calgary. Dr. Coffey, VP Product Development for the Company was instrumental in these discoveri...

More Information about "Oncolytics" on BioPortfolio

We have published hundreds of Oncolytics news stories on BioPortfolio along with dozens of Oncolytics Clinical Trials and PubMed Articles about Oncolytics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oncolytics Companies in our database. You can also find out about relevant Oncolytics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record